MTOR Kinase Inhibitor Sensitizes T-cell Lymphoblastic Leukemia for Chemotherapy-induced DNA Damage Via Suppressing FANCD2 Expression

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Jul 16

PMID 23852546

Citations 12

Authors

F Guo

J Li

S Zhang

W Du

S Amarachintha

J Sipple

J Phelan

H L Grimes

Y Zheng

Q Pang

Affiliations

Soon will be listed here.

Citing Articles

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.

Taylor S, Arends M, Langdon S Explor Target Antitumor Ther. 2022; 1(1):26-52.

PMID: 36046263 PMC: 9400734. DOI: 10.37349/etat.2020.00003.

Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia.

Wu L, Chatla S, Lin Q, Chowdhury F, Geldenhuys W, Du W Nat Commun. 2021; 12(1):6936.

PMID: 34836965 PMC: 8626516. DOI: 10.1038/s41467-021-27300-w.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely J Oncotarget. 2018; 9(51):29587-29600.

PMID: 30038706 PMC: 6049870. DOI: 10.18632/oncotarget.25640.

mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.

Silvera D, Ernlund A, Arju R, Connolly E, Volta V, Wang J Mol Cell Biol. 2016; 37(5).

PMID: 27956700 PMC: 5311240. DOI: 10.1128/MCB.00577-16.

Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer.

Shen Y, Zhang J, Yu H, Fei P Cancer Cell Microenviron. 2015; 2(4).

PMID: 26640811 PMC: 4667986. DOI: 10.14800/ccm.986.

References

Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J . The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and.... J Biol Chem. 2012; 287(26):21796-805. PMC: 3381142. DOI: 10.1074/jbc.M111.304626. View

Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas V . Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2004; 105(6):2527-34. DOI: 10.1182/blood-2004-06-2494. View

Foster K, Fingar D . Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010; 285(19):14071-7. PMC: 2863215. DOI: 10.1074/jbc.R109.094003. View

Xu Q, Thompson J, Carroll M . mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005; 106(13):4261-8. PMC: 1895255. DOI: 10.1182/blood-2004-11-4468. View

Proud C . The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst). 2004; 3(8-9):927-34. DOI: 10.1016/j.dnarep.2004.03.012. View

Hay N . The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3):179-83. DOI: 10.1016/j.ccr.2005.08.008. View

Perl A, Kasner M, Tsai D, Vogl D, Loren A, Schuster S . A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2009; 15(21):6732-9. DOI: 10.1158/1078-0432.CCR-09-0842. View

Kee Y, DAndrea A . Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012; 122(11):3799-806. PMC: 3484428. DOI: 10.1172/JCI58321. View

Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E . Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 2011; 25(5):781-91. DOI: 10.1038/leu.2011.20. View

10.

Falcon B, Barr S, Gokhale P, Chou J, Fogarty J, Depeille P . Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011; 71(5):1573-83. PMC: 3077087. DOI: 10.1158/0008-5472.CAN-10-3126. View

11.

Yu K, Toral-Barza L, Shi C, Zhang W, Lucas J, Shor B . Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009; 69(15):6232-40. DOI: 10.1158/0008-5472.CAN-09-0299. View

12.

Ciuffreda L, Di Sanza C, Incani U, Milella M . The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010; 10(5):484-95. DOI: 10.2174/156800910791517172. View

13.

Guertin D, Sabatini D . Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008. View

14.

Seif A . Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011; 204(5):227-44. DOI: 10.1016/j.cancergen.2011.04.005. View